NAGE

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BiologicalAge--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® (patented nicotinamide riboside, NR) supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock. In additi.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 46th Annual Growth Conference, taking place from August 11 to 13, 2026, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 11, at 2:00 p.m.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicot.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which.

Investors need to pay close attention to NAGE stock based on the movements in the options market lately.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, Niagen® (patented nicotinamide riboside, or NR), the mos.